Introduction to supplement: the current status of treatment for ALS

Robert G. Miller, Stanley H. Appel

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


ALS is a lethal neurodegenerative disease wherein the diagnosis is often delayed. Our understanding of the pathobiology is slowly expanding, and the number of new genes is rapidly increasing. The development of potential treatments targeting specific mechanisms is beginning to offer hope. Evidence-based treatments and the development of quality measures have raised the standard of care. The current status of treatment for ALS includes one drug riluzole that slows progression modestly, and another drug edaravone that was recently approved by FDA to slow ALS progression. Multidisciplinary clinics and symptomatic treatments ease the burden of ALS and prolong life. An overview of these treatments is provided here.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
StatePublished - Oct 31 2017


  • Treatment
  • amyotrohpic lateral sclerosis
  • clinical trials
  • multidisciplinary clinics
  • practice parameters
  • quality measures

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Introduction to supplement: the current status of treatment for ALS'. Together they form a unique fingerprint.

Cite this